Larisa V Debelenko
Affiliation: St. Jude Children's Research Hospital
- p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndromeLarisa V Debelenko
Department of Pathology, Children s Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA
Pediatr Dev Pathol 13:218-24. 2010..Recognition of this lesion and its association is important for early diagnosis and subsequent tumor surveillance in the proband and affected family members...
- D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendotheliomaLarisa V Debelenko
Department of Pathology, Children s Hospital, Harvard Medical School, Boston, MA, USA
Mod Pathol 18:1454-60. 2005..Further studies are necessary to define the identity of the D2-40 antigen and to elucidate the biologic significance of its selective lymphothelial reactivity....
- A novel EWSR1-CREB3L1 fusion transcript in a case of small cell osteosarcomaLarisa V Debelenko
Department of Pathology, Wayne State University, Detroit, MI, USA
Genes Chromosomes Cancer 50:1054-62. 2011..The 3'-end partner and the inferred structure of EWSR1-CREB3L1, however, are different from those of Ewing sarcoma, suggesting different targets of the new oncogene...
- Novel karyotypes in giant cell-rich lesions of boneBriana C Gleason
Department of Pathology, Children s Hospital, Boston, MA 02115, USA
Am J Surg Pathol 31:926-32. 2007..Further cytogenetic characterization of giant cell-rich bone lesions may improve the utility of karyotyping as a tool in their differential diagnosis and may shed light on the pathogenetic relationship between these lesions...
- Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrumLarisa V Debelenko
Department of Pathology, St Jude Children s Research Hospital, Memphis, TN, USA
Mod Pathol 24:430-42. 2011..The results should prompt further studies to advance the molecular classification of renal cell carcinoma and help to select patients who would benefit from appropriate targeted therapies...